Skip to main content

Table 9 Patient’s characteristics according to age groups

From: Optimal radiotherapy for patients with internal mammary lymph node metastasis from breast cancer

CharacteristicsNumber of patients (%)p-value
≤ 40 years
(n = 38)
>  40 years(n = 46)
Follow-up durationMedian months (range)58.5 mo (15–111)59.0 mo (12–104)0.215 1)
Histologic grade1–222 (57.9%)23 (50.0%)0.163
310 (26.3%)20 (43.5%)
SubtypesNon-TNBC25 (65.8%)29 (63.0%)0.974
TNBC13 (34.2%)17 (37.0%)
cT stages1–227 (71.1%)28 (60.9%)0.916
3–411 (28.9%)18 (39.1%)
cN stages2b or 3b27 (71.1%)36 (78.3%)0.613
3c11 (28.9%)10 (21.7%)
FNABx for IMN(−) or unknown16 (42.1%)28 (60.9%)0.135
(+)22 (57.9%)18 (39.1%)
Extent of the IMNSingle ICS18 (47.4%)19 (41.3%)0.737
Multiple ICS20 (52.6%)27 (58.7%)
IMN long diameter<  1.0 cm20 (52.6%)22 (47.8%)0.826
≥ 1.0 cm18 (47.4%)24 (52.2%)
Neoadjuvant chemotherapyNot done7 (18.4%)11 (23.9%)0.731
Done31 (81.6%)35 (76.1%)
Primary surgeryBCS20 (52.6%)20 (43.5%)0.538
Mastectomy18 (47.4%)26 (56.5%)
Axillary surgeryALND32 (84.2%)42 (91.3%)0.509
SLNB6 (15.8%)4 (8.7%)
RT dose to IMN 2)50–63.5 Gy15 (39.5%)20 (43.5%)0.882
63.6–70.4 Gy23 (60.5%)26 (56.5%)
  1. 1)By the Mann-Whitney U-test
  2. 2)Radiotherapy dose was calculated using the biologically equivalent dose in 2 Gy fractions (EQD2) assuming the α/β ratio of 3.5 Gy
  3. Abbreviations: mo Months, TNBC Triple-negative breast cancer, IMN Internal mammary node, FNABx Fine needle aspiration biopsy, ICS Intercostal space, BCS Breast conserving surgery, ALND Axillary lymph node dissection, SLNB Sentinel lymph node biopsy